JP2008514925A5 - - Google Patents

Download PDF

Info

Publication number
JP2008514925A5
JP2008514925A5 JP2007533654A JP2007533654A JP2008514925A5 JP 2008514925 A5 JP2008514925 A5 JP 2008514925A5 JP 2007533654 A JP2007533654 A JP 2007533654A JP 2007533654 A JP2007533654 A JP 2007533654A JP 2008514925 A5 JP2008514925 A5 JP 2008514925A5
Authority
JP
Japan
Prior art keywords
ephb4
cell
tumor
gene
test cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007533654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514925A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/034179 external-priority patent/WO2006034456A2/en
Publication of JP2008514925A publication Critical patent/JP2008514925A/ja
Publication of JP2008514925A5 publication Critical patent/JP2008514925A5/ja
Abandoned legal-status Critical Current

Links

JP2007533654A 2004-09-23 2005-09-23 腫瘍を検出し且つ治療するための組成物及び方法 Abandoned JP2008514925A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61286104P 2004-09-23 2004-09-23
PCT/US2005/034179 WO2006034456A2 (en) 2004-09-23 2005-09-23 Compositions and methods for detecting and treating tumors

Publications (2)

Publication Number Publication Date
JP2008514925A JP2008514925A (ja) 2008-05-08
JP2008514925A5 true JP2008514925A5 (enExample) 2008-11-13

Family

ID=36090700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533654A Abandoned JP2008514925A (ja) 2004-09-23 2005-09-23 腫瘍を検出し且つ治療するための組成物及び方法

Country Status (6)

Country Link
US (1) US20060194220A1 (enExample)
EP (1) EP1799867A2 (enExample)
JP (1) JP2008514925A (enExample)
AU (1) AU2005286663A1 (enExample)
CA (1) CA2581430A1 (enExample)
WO (1) WO2006034456A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006294873A1 (en) * 2005-09-23 2007-04-05 Vasgene Therapeutics, Inc. Use of EphrinB2 directed agents for the treatment or prevention of viral infections
JP2008289456A (ja) * 2006-06-16 2008-12-04 Sysmex Corp がん細胞の検出方法及び装置
US20070292882A1 (en) * 2006-06-16 2007-12-20 Sysmex Corporation Method and apparatus for detecting cancer cell
US7662566B2 (en) * 2006-11-22 2010-02-16 Myriad Genetics, Inc. Gene copy number profiling
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
PL2492355T3 (pl) * 2007-11-29 2015-09-30 Molecular Health Gmbh Receptor erytropoetyny ochronny dla tkanki (nepor) i sposoby zastosowania
JP5610125B2 (ja) * 2010-02-22 2014-10-22 国立大学法人 長崎大学 癌転移の検出方法および検出用キット
GB201616640D0 (en) * 2016-09-30 2016-11-16 Sarphie David And Mian Rubina Monitoring cancer recurrence and progression
WO2018224688A1 (en) * 2017-06-08 2018-12-13 Lumito Ab A method of analysing a sample for at least one analyte
EP3830742B1 (en) 2018-07-27 2025-02-26 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis
JP7464977B2 (ja) * 2020-06-10 2024-04-10 国立大学法人東京農工大学 イヌ中皮腫細胞株
EP4105328A1 (en) * 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6331302B1 (en) * 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6413730B1 (en) * 1996-07-05 2002-07-02 Mount Sinai Hospital Corporation Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2452578A1 (en) * 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
EP1606305A4 (en) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH

Similar Documents

Publication Publication Date Title
Weiss et al. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival
Pattamadilok et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer
JP2019196400A5 (enExample)
PT2195450E (pt) Métodos de utilização de miarn para detecção de morte celular in vivo
JP2004518429A (ja) Ｅｒｃｃ１発現に基づく化学療法による処方の決定方法
JP2015526074A (ja) Ｊａｋ／ｓｔａｔ阻害剤に対する治療反応の予測
KR20030081339A (ko) Ｅｒｃｃ１ 및 ｔｓ 발현을 기초로 한 화학요법 섭생을결정하는 방법
JP2008118915A (ja) 胃癌高発現遺伝子特定による胃癌診断および創薬への利用
JP2006518186A5 (enExample)
AU2020201779B2 (en) Method for using gene expression to determine prognosis of prostate cancer
Tsutsumi et al. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer
CN107586850B (zh) 非编码基因在肝癌诊疗中的应用
CN107177676A (zh) 长链非编码rna nonhsat113026用于肾癌诊断分子标志物的用途
EP0701629B1 (en) Bc200 rna, probes therefor and use thereof
JP5865241B2 (ja) 肉腫の予後分子署名およびその使用
CN113549686A (zh) 一种钙离子拮抗剂代谢标志物的检测试剂盒及其检测方法和应用
JP2006501465A5 (enExample)
JP5546064B2 (ja) 肺がん予後および薬物調製における２つのマイクロＲＮＡｓの使用
US8206920B2 (en) Diagnostic assay for the specific treatment of acute myeloid leukemia
RU2005127807A (ru) Применение нового полиморфизма в гене hsgki для диагностики гипертонии и применение генов семейства sgk для диагностики и терапии синдрома удлиненного q/t-периода
JP2006520587A5 (enExample)
CN105838797B (zh) 一种诊治食管癌的分子标志物
CN111808961B (zh) 一种用于检测肝癌的生物标志物组及其应用
KR102254614B1 (ko) 흑염소 품종식별용 snp 마커 및 이의 용도
CN109913552B (zh) 一种食管鳞癌诊疗靶点及应用